



ATTORNEY'S DOCKET NO. C01039.70053.US

#10
B
1-22-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Krieg et al.
Serial No.: 09/931,583
Confirmation No.: 2288
Filed: August 16, 2001
For: METHODS AND PRODUCTS FOR TREATING HIV INFECTION
Examiner: Dave Nguyen
Art Unit: 1632

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 13th day of January, 2003.

Yvonne M. Lingb
Yvonne M. Lingb

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JAN 22 2003

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement dated December 17, 2002 (Paper No. 9),
Applicants hereby request entry of the following Election.

ELECTION

Applicants hereby elect the claims of Group I (claims 1-39 and 54, drawn to combination therapy of treating an HIV-infected patient). As further required by the Examiner upon election of Group I, Applicants further elect the following specific species:

- protease inhibitors, as recited in claim 7;
- anti-HIV therapy is terminated at least one week after the initial administration of CpG, as recited in claim 16; and
- an adjuvant-type CpG nucleic acid SEQ ID NO:29 (TCGTCGTTTTGTCGTTTTGTCGTT), as recited in claim 3.